Table 3.

Prevalence (%) of Selected Predictors of Low-Density Lipoprotein Cholesterol Goal Achievement According to Ethnicity and Risk Category

	Ethnicity	Prevalence (%)
		0 to 1 Risk Factor	2+ Risk Factors	CHD+CHD RE	Total
Female gender	NHW	57.8	43.9	35.8	41.8
	AA	73.5	57.0	49.2	54.9
	P-value*	.01	.02	<.001	<.001
Body mass index≥30 kg/m2	NHW	34.9	43.6	53.4	47.4
	AA	44.1	54.7	63.8	58.6
	P-value*	.13	.05	.002	<.001
Triglycerides≥2.26 mmol/L	NHW	19.2	26.8	28.0	26.1
	AA	13.2	8.1	14.2	12.7
	P-value*	.23	<.001	<.001	<.001
Diabetes mellitus	NHW	0	0	50.9	27.8
	AA	0	0	75.6	47.1
	P-value*	–	–	<.001	<.001
Receipt of diet recommendations	NHW	79.3	81.5	81.5	81.1
	AA	86.8	80.2	79.9	81.1
	P-value*	.15	.76	.54	.99
Compliant with diet therapy†	NHW	69.2	72.4	67.8	69.3
	AA	72.1	76.7	68.1	70.6
	P-value*	.62	.38	.92	.60
Lipid drug therapy	NHW	75.7	86.4	92.2	87.7
	AA	70.6	87.2	86.6	84.1
	P-value*	.35	.83	.002	.03
High-efficacy statin therapy‡	NHW	54.8	62.1	67.3	63.7
	AA	45.6	54.7	62.2	57.8
	P-value*	.21	.02	.14	.007
Treatment by a subspecialist	NHW	5.1	8.3	25.7	17.3
	AA	1.5	5.8	9.1	7.1
	P-value*	.18	.43	<.001	<.001

^*P-values for risk categories derived from logistic regression models for each risk category. P-values in the “Total” column are for the ethnicity term in models containing terms for ethnicity, risk category and, where significant, ethnicity by risk category interaction.

^†Received diet instruction and compliant according to physician judgment.

^‡Atorvastatin and simvastatin (rosuvastatin was not yet cleared for marketing at the time this survey was completed) were operationally defined as high-efficacy statins. Lovastatin, fluvastatin and pravastatin are considered lower-efficacy statins.

CHD RE, coronary heart disease risk equivalents; NHW, non-Hispanic white; AA, African American.